ES2527358T3 - Compuesto para el tratamiento de cáncer cerebral - Google Patents

Compuesto para el tratamiento de cáncer cerebral Download PDF

Info

Publication number
ES2527358T3
ES2527358T3 ES11748101.0T ES11748101T ES2527358T3 ES 2527358 T3 ES2527358 T3 ES 2527358T3 ES 11748101 T ES11748101 T ES 11748101T ES 2527358 T3 ES2527358 T3 ES 2527358T3
Authority
ES
Spain
Prior art keywords
brain cancer
compound
treatment
formula
represents hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11748101.0T
Other languages
English (en)
Inventor
Hooshmand Sheshbaradaran
Rebecca Baerga
Jenel Cobb
Seied Mojtaba Valiahdi
Bernhard Keppler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niiki Pharma Inc
Original Assignee
Niiki Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niiki Pharma Inc filed Critical Niiki Pharma Inc
Application granted granted Critical
Publication of ES2527358T3 publication Critical patent/ES2527358T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un compuesto de fórmula (I)**Fórmula** en donde R1 representa hidrógeno, un halógeno o un grupo sulfono SO3M, en el que M es un ión metálico, y R2 representa hidrógeno, o R1 es Cl y R2 es I, o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de cáncer cerebral, en donde dicho cáncer cerebral es un cáncer cerebral resistente, y además en donde dicho cáncer cerebral se trató previamente con BCNU (bis-cloronitrosourea).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
    imagen2
ES11748101.0T 2010-02-26 2011-02-25 Compuesto para el tratamiento de cáncer cerebral Active ES2527358T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30881310P 2010-02-26 2010-02-26
US308813P 2010-02-26
US41488210P 2010-11-17 2010-11-17
US414882P 2010-11-17
PCT/US2011/026144 WO2011106577A2 (en) 2010-02-26 2011-02-25 Method for treating brain cancer

Publications (1)

Publication Number Publication Date
ES2527358T3 true ES2527358T3 (es) 2015-01-22

Family

ID=44507571

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11748101.0T Active ES2527358T3 (es) 2010-02-26 2011-02-25 Compuesto para el tratamiento de cáncer cerebral

Country Status (6)

Country Link
US (2) US20130090321A1 (es)
EP (1) EP2538944B1 (es)
JP (1) JP2013521229A (es)
CN (1) CN103108636A (es)
ES (1) ES2527358T3 (es)
WO (1) WO2011106577A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133479A2 (en) * 2010-04-19 2011-10-27 Niiki Pharma Inc. Combination therapy with a proteasome inhibitor and a gallium complex
WO2019060152A1 (en) 2017-09-20 2019-03-28 Oklahoma Medical Research Foundation TREATMENT OF DRUG-RESISTANT GLIOMES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69225484T2 (de) * 1991-07-25 1998-12-10 Philippe Reims Collery Gallium iii komplexe, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
AT503317B1 (de) * 2006-02-13 2007-09-15 Faustus Forschung Translationa Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen
CA2672147A1 (en) * 2006-07-27 2008-01-31 University Of Virginia Patent Foundation System and method for intracranial implantation of therapeutic or diagnostic agents
CN101678002A (zh) * 2007-05-08 2010-03-24 先灵公司 使用含有替莫唑胺的静脉注射用配制剂的治疗方法
US20110318265A1 (en) * 2009-04-07 2011-12-29 Bernstein Lawrence R Coupled identification and treatment of cancer
WO2011133479A2 (en) * 2010-04-19 2011-10-27 Niiki Pharma Inc. Combination therapy with a proteasome inhibitor and a gallium complex

Also Published As

Publication number Publication date
EP2538944A4 (en) 2013-08-28
WO2011106577A3 (en) 2012-01-12
JP2013521229A (ja) 2013-06-10
EP2538944A2 (en) 2013-01-02
CN103108636A (zh) 2013-05-15
WO2011106577A2 (en) 2011-09-01
EP2538944B1 (en) 2014-10-22
US20130090321A1 (en) 2013-04-11
US20130310356A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
SV2016005229A (es) Inhibidores de syk
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
AR103680A1 (es) Inhibidores selectivos de bace1
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR096148A1 (es) Terapia combinada para el tratamiento del cáncer
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ES2527358T3 (es) Compuesto para el tratamiento de cáncer cerebral